Company profile
Enlivex Ltd.
NASDAQ:ENLVBiotechnology: Pharmaceutical Preparations
Clinical trials (9)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05581719 | phase1_2 | terminated | 2022-11-15 | 2024-04-15 | Enlivex Therapeutics RDO Ltd. | A Phase 1/2a Study Evaluating Allocetra-OTS as Monotherapy or in Combination With Anti-PD-1 Therapy for the Treatment of Advanced Solid Tumor Malignancy |
| NCT04612413 | phase2 | completed | 2020-11-30 | 2024-01-12 | Enlivex Therapeutics Ltd. | A Phase 2 Study Evaluating Efficacy, Safety and Tolerability of Different Doses and Regimens of Allocetra-OTS for the Treatment of Organ Failure in Adult Sepsis Patients |
| NCT04922957 | phase2 | terminated | 2021-09-01 | 2022-04-01 | Enlivex Therapeutics Ltd. | A Phase 2b Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study, Evaluating Efficacy and Safety of Allocetra-OTS in Patients With Severe or Critical COVID-19 With Associated Acute Respiratory Distress Syndrome (ARDS) |
| NCT06522035 | phase1 | terminated | 2024-08-01 | 2025-10-20 | Enlivex Therapeutics Ltd. | Evaluation of Allocetra by Intra-articular Injection for the Treatment of Psoriatic Arthritis |
| NCT07580716 | phase2 | recruiting | 2026-05-01 | 2027-02-01 | Enlivex Therapeutics Ltd. | Intra-Articular Allocetra in Patients With Primary Knee Osteoarthritis |
FDA applications (0)
No records yet.